Lipotec, S.a.

Lubrizol Advanced Materials, Inc.

Universidad Miguel Hernández De Elche

Consejo Superior De Investigaciones Cientificas

Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.

Bcn Peptides S.a.

Lipotec Sau

Diverdrugs, S.l

Lipotech, S.a.

Antalgenics, S.l.

Puig, S.a.

Antonio Vicente Ferrer Montiel

Cristina Carreño Serraïma

Juan Cebrián Puche

Nuria Almiñana Domenech

Wim Van Den Nest

Raquel Delgado González

José María García Antón

Gregorio Fernández Ballester

Albert Soley Astals

Núria Almiñana Doménech

Félix Viana De La Iglesia

Asia Fernández Carvajal

Gregorio Joaquin Fernandez Ballester

Nuria Garcia Sanz

Isabel Devesa Giner

Juana Gallar Martinez

Carlos Belmonte Martínez

Nuria Almiñana Doménech

Giorgina Mangano

Francesca Mancini

Ángel Messeguer Peypoch

Armando Genazzani

Núria Almiñana Domènech

Cristina Bartella

Teresa Carbonell Castello

Luis Miguel Gutierrez Perez

Salvador Viniegra Bover

Rosa Ma Planell Cases

Ana Isabel Gil Tebar

Ma Mercedes Llobregat Hernandez

Enrique Perez Paya

Asia Fernandez Carvajal

Ana Sempere Bonete

Núria García Sanz

Juana Gallar Martínez

Berta Ponsati Obiols

Arturo Puig Montiel

Raquel Delgado Gonzalez

David Panyella Costa

Tracey Pirali

Josep Farrera-Sinfreu

Carlos Belmonte Martinez

Gian Cesare Tron

Mauricio Valerio Santiago

Consuelo García Hernández

Leslie Matalonga Borrel

Laura Gort Mas

Ma Clara Blaines Mira

Roberto Pascual Martínez

Antonia Ribes Rubió

Catalina Rodríguez Bielsa

María Del Carmen Lidón Moya

José Ginestar González

Ma Clara Blanes Mira

Cristina Carreño Serrïma

Marc Esplugas Gonzalez

Olga Laporta Alcantara

Nuria García Sanz

Maria Del Carmen Lidon

Valentina Mercalli

Roberto De La Torre

Carlos Belmonte Martnez

Nuria Alminaña Doménech

Cristina Carreno SERRAÏMA

Cristina Carreno Serraima

Maria CamprubÍ Robles

Jimena FERNÁNDEZ Carneado

Olga Laporta ALCÁNTARA

Cristina CARREÑO SERRAÏMA

Raquel Delgado GONZÁLEZ

Núria ALMIÑANA Domenech

José Maria García Anton

M Clara Blanes Mira

M Mercedes Llobregat Hernandez

Rosa M Planell Cases

Teresa Carbonell Castell

Núria ALMIÑANA DOMÉNECH

M Nuria GARCÍA Sanz

Marc Esplugas GONZÁLEZ

Núria GARCÍA Sanz

María Del Carmen LIDÓN Moya

Cristina Carreno Serraiema

Antonia Ribes Rubio

Roberto Pascual Martinez

Jimena Fernandez Carneado

Maria Camprubi Robes

Berta Ponsati Obliols

Jose Maria Garcia Anton

Gregorio Fernandez Ballester

The invention relates to peptides capable of inhibiting neuronal exocytosis and to products comprising such peptides, in particular pharmaceutical and cosmetic products useful for ameliorating skin conditions, disorders and/or diseases mediated by neuronal exocytosis, such as wrinkles, excessive perspiration, pruritus, cutaneous inflammation, dermatitis, atopia, psoriasis, vascular hyperreactivity, rosacea, acne, hair growth, wound healing, calluses, warts, or sensitive skin conditions, such as ulcers and lesions on the skin.

Peptides for inhibiting cholinergic calcitonin gene-related peptide (CGRP) and acetylcholine (ACH) release or inhibiting sensitization-mediated by TRPV1-mediated excitability in sensory neurons and methods of use thereof

Peptides able to inhibit the muscarinic receptor M3 activity and to products comprising such peptides, in particular pharmaceutical and cosmetic products useful for ameliorating skin conditions mediated by the muscarinic receptor M3 activity, such as excessive perspiration, inflammation, sebum production, and cell adhesion, motility, growth, differentiation and proliferation.

Peptides having inhibitory activity on muscarinic receptor M3

A compound of formula (1) R—W—X-AA-AA-AA-AA-AA-AA-AA-AA-AA-Y—Z—R, wherein AAis Phe; AAis Trp; AAis selected from Met, Leu and lie; AAis selected from Lys, Arg and Gln; AAis Arg; AAis Lys; AAis selected from Arg, Lys and His; AAis selected from Val, Ile, Leu and Met; and AAis Pro. The compound is useful in the treatment and/or care of the skin, hair, nails and/or mucous membranes, in particular for improving the barrier function of the skin, for energizing the skin and as an anti-aging agent.

Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes

The invention provides a therapy for lysosomal storage diseases and glycogenosis by treatment with compounds that promote exocytosis, preferably lysosomal exocytosis. The treatment of cells from patients affected by different lysosomal storage disorders with exocytosis activating compounds leads to a decrease in the accumulation of toxic substrate in the lysosomes, thus allowing the treatment, prevention and relief of the symptoms of many lysosomal storage disorders.

Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis

The present invention relates to TRPV1 modulator compounds of formula (I) or their pharmaceutically, veterinary or cosmetically acceptable salts, or their stereoisomers or mixtures thereof, wherein m is an integer selected from 1 to 3; R, R, Rand Rare independently selected from H, (C-C)alkyl, unsaturated (C-C)hydrocarbon, and (C-C)cycloalkyl, being these groups optionally substituted; Ris hydrogen or halogen; Ris selected from H, (C-C)alkyl, unsaturated (C-C)hydrocarbon, (C-C)cycloalkyl, (C-C)aryl, and (C-C)heteroaryl, being these groups optionally substituted; and Ris selected from (C-C)alkyl, unsaturated (C-C)hydrocarbon, (C-C)aryl, and (C-C)heteroaryl, being these groups optionally substituted. It also relates to a process for their preparation, to pharmaceutical, veterinary or cosmetic compositions containing them, and to their pharmaceutical, veterinary and cosmetic applications. 

TRPV1 modulator compounds

The invention relates to compounds having formula (I) wherein A is selected from the group consisting of: a) optionally substituted (C-C) alkyl; b) optionally substituted (C-C) cycloalkyl; c) optionally substituted (C-C) aryl; d) optionally substituted (C-C) heteroaryl; e) C(O)&#x2014;(C-C) aryl, in which group (C-C) aryl is optionally substituted; f) C(O)&#x2014;(C-C) heteroaryl, in which group (C-C) heteroaryl is optionally substituted; g) CH(OH)&#x2014;(C-C) aryl, in which group (C-C) aryl is optionally substituted; and h) CH(OH)&#x2014;(C-C) heteroaryl, in which group (C-C) heteroaryl is optionally substituted. The invention also relates to methods for the production of said compounds, to pharmaceutical and veterinary compositions comprising said compounds and to the therapeutic uses thereof, such as for the prevention and/or treatment of dry eye syndrome, vaginal dryness and/or burning mouth syndrome.

TRPM8 receptor agonist compounds and uses thereof

Compounds of general formula (I): R1-Wm-Xn-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, and in processes of treatment and/or care of the skin, hair and/or mucous membranes, in particular in the aging and photoaging of the skin.

Compounds useful in the treatment and/or care of the skin, hair, nails, and/or mucous membranes

Exopolysaccharide of a bacterial strain for its use in treatment and/or care of the skin, as well as its cosmetic and/or dermopharmaceutical compositions. In particular, its use for inflammation, lipolysis, lipid accumulation and skin firmness.

Exopolysaccharide for the treatment and/or care of the skin, culture media and compositions

A method of treatment and/or care of the skin includes administering a composition which includes a cosmetically or dermopharmaceutically effective quantity (between 0.000001% by weight and 5% by weight of the composition) of an exopolysaccharide produced by a strain of, or a ferment extract comprising the exopolysaccharide. The exopolysaccharide has a composition by weight of 0.5% to 45% of rhamnose, 0.1% to 25% of galactose, 0.5% to 30% of mannose, 50% to 95% for the sum of glucose and D-glucosamine, 0% to 10% of fucose and 0% to 12% of glucuronic acid, with the condition that the sum of the percentages does not exceed 100%.

Cosmetic composition containing halomonas ferment extract, and use thereof

Extract of a bacterial strain for its use in treatment and/or care of the skin and/or mucous membranes, as well as its cosmetic and/or dermopharmaceutical compositions. In particular, its use for sebum reduction and skin firmness.

Cosmetic and/or pharmaceutical composition containing a bacterial extracellular product from pseudoalteromonas antarctica, and use thereof

A ferment extract of a bacterial strain of thespecies, a method of treatment and/or care of the skin and/or muscles, and cosmetic and/or dermopharmaceutical compositions containing the ferment extract. In particular, the ferment extract is used for muscular endurance, wound healing and skin firmness.

Ferment extract of a bacterial strain for the increase of adiponectin levels

Compounds of general formula (I): R&#x2014;W&#x2014;X-AA-AA-AA-AA-AA-AA-AA-Y&#x2014;Z&#x2014;R, their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.

Compounds which inhibit neuronal exocytosis

The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

Methods for treating occular irritation involving tearing by administering modulators of TRPM8

Method for treating vaginal dryness by administering transient receptor potential cation channel subfamily M member 8 (TRPM8) receptor agonists

Compounds of general formula (I): R-W-X-AA-AA-AA-AA-AA-AA-AA-AA-AA-Y-Z-R(I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.

Growing community of inventors

Alicante, Spain

Antonio Vicente Ferrer Montiel